NASDAQ:VALN Valneva (VALN) Stock Price, News & Analysis → Fidelity, Bezos, Goldman Bet Big on Tiny Biotech (From Behind the Markets) (Ad) Free VALN Stock Alerts $7.24 -0.26 (-3.47%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$7.08▼$7.3750-Day Range$6.63▼$8.8952-Week Range$6.58▼$17.05Volume19,120 shsAverage Volume11,216 shsMarket Capitalization$504.19 millionP/E RatioN/ADividend YieldN/APrice Target$21.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Valneva alerts: Email Address Valneva MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside199.3% Upside$21.67 Price TargetShort InterestBearish0.07% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.35Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.11 to ($1.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.30 out of 5 starsMedical Sector710th out of 905 stocksBiological Products, Except Diagnostic Industry120th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingValneva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageValneva has only been the subject of 2 research reports in the past 90 days.Read more about Valneva's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.07% of the float of Valneva has been sold short.Short Interest Ratio / Days to CoverValneva has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Valneva has recently increased by 4.00%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldValneva does not currently pay a dividend.Dividend GrowthValneva does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VALN. Previous Next 2.4 News and Social Media Coverage News SentimentValneva has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Valneva this week, compared to 3 articles on an average week.Search Interest2 people have searched for VALN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Valneva to their MarketBeat watchlist in the last 30 days. This is a decrease of -91% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Valneva insiders have not sold or bought any company stock.Percentage Held by Insiders14.91% of the stock of Valneva is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.39% of the stock of Valneva is held by institutions.Read more about Valneva's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Valneva are expected to decrease in the coming year, from $0.11 to ($1.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Valneva is -4.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Valneva is -4.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioValneva has a P/B Ratio of 3.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Valneva's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThe new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.Pay close attention to this important video About Valneva Stock (NASDAQ:VALN)Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.Read More VALN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VALN Stock News HeadlinesMay 7, 2024 | markets.businessinsider.comWhat Wall Street expects from Valneva SE (spons ADRs)'s earningsMay 7, 2024 | markets.businessinsider.comValneva earnings preview: what to expectMay 8, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. May 7, 2024 | finance.yahoo.comValneva Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesMay 7, 2024 | globenewswire.comValneva Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesMay 6, 2024 | finance.yahoo.comDeclaration of shares and voting rights April 30, 2024 - VALNEVA SEMay 3, 2024 | americanbankingnews.comValneva (NASDAQ:VALN) Shares Gap Up to $7.45April 29, 2024 | ft.comLyme disease bites as ticks gain ground in USMay 8, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 4, 2024 | finance.yahoo.comDeclaration of voting rights - Valneva SE, March 2024March 27, 2024 | msn.comValneva commences Phase I trial of second-generation Zika vaccineMarch 27, 2024 | markets.businessinsider.comBuy Rating on Valneva Supported by Promising Vaccine Developments and Solid Revenue ProjectionsMarch 26, 2024 | globenewswire.comValneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine CandidateMarch 25, 2024 | msn.com2 new Lyme disease vaccines could mean end of debilitating illnessMarch 25, 2024 | globenewswire.comValneva Announces Filing of 2023 Universal Registration Document and US Form 20-FMarch 22, 2024 | seekingalpha.comValneva SE (VALN) Q4 2023 Earnings Call TranscriptMarch 22, 2024 | markets.businessinsider.comWhat Analysts Are Saying About Valneva StockMarch 21, 2024 | markets.businessinsider.comBuy Rating Affirmed for Valneva: Strong Core Growth and Strategic Financial HealthMarch 21, 2024 | finance.yahoo.comValneva SE (NASDAQ:VALN) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | globenewswire.comValneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.March 20, 2024 | msn.comValneva guides for nearly double product sales by 2026March 20, 2024 | investorplace.comVALN Stock Earnings: Valneva Misses Revenue for Q4 2023March 20, 2024 | msn.comValneva GAAP EPS of -€0.73, revenue of €153.71M; updates FY24 guidanceMarch 20, 2024 | finance.yahoo.comValneva Reports Full Year 2023 Results and Provides Business Updates and OutlookMarch 20, 2024 | reuters.comFrench biotech company Valneva raises product sales guidanceMarch 20, 2024 | globenewswire.comValneva Reports Full Year 2023 Results and Provides Business Updates and OutlookMarch 19, 2024 | msn.comWest Lothian sciences firm bags brace of awardsSee More Headlines Receive VALN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Valneva and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2024Today5/08/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VALN CUSIPN/A CIK1836564 Webvalneva.com Phone33-2-28-07-37-10FaxN/AEmployees676Year FoundedN/APrice Target and Rating Average Stock Price Target$21.67 High Stock Price Target$26.00 Low Stock Price Target$17.00 Potential Upside/Downside+199.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.58) Trailing P/E RatioN/A Forward P/E Ratio65.82 P/E GrowthN/ANet Income$-109,780,000.00 Net Margins-65.99% Pretax Margin-64.16% Return on Equity-59.48% Return on Assets-19.17% Debt Debt-to-Equity Ratio1.04 Current Ratio1.65 Quick Ratio1.37 Sales & Book Value Annual Sales$165.52 million Price / Sales3.05 Cash FlowN/A Price / Cash FlowN/A Book Value$2.00 per share Price / Book3.62Miscellaneous Outstanding Shares69,640,000Free Float59,255,000Market Cap$504.19 million OptionableNot Optionable Beta2.22 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Thomas Lingelbach (Age 61)President, CEO & Director Comp: $981.08kMr. Peter Buhler (Age 53)Chief Financial Officer Comp: $596.22kMr. Frederic Jacotot (Age 60)VP of Legal & IP, General Counsel, and Corporate Secretary Comp: $325.62kMr. Franck Grimaud MBA (Age 57)Chief Business Officer Comp: $428.19kDr. Juan-Carlos Jaramillo M.D. (Age 52)Chief Medical Officer Comp: $575.87kMs. Dipal Patel (Age 49)Chief Commercial Officer Comp: $551.33kMr. Vincent Dequenne (Age 57)Chief Operating Officer Mr. Joshua Drumm Ph.D.Vice President of Investor RelationsMs. Laetitia Bachelot-FontaineVP of Global Communications & European Investor RelationsMs. Petra Pesendorfer (Age 38)Chief People Officer More ExecutivesKey CompetitorsProKidneyNASDAQ:PROKAlectorNASDAQ:ALECAllogene TherapeuticsNASDAQ:ALLOHumacyteNASDAQ:HUMAVoyager TherapeuticsNASDAQ:VYGRView All CompetitorsInstitutional OwnershipGeneral American Investors Co. Inc.Bought 9,361 shares on 5/3/2024Ownership: 0.509%View All Institutional Transactions VALN Stock Analysis - Frequently Asked Questions Should I buy or sell Valneva stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Valneva in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VALN shares. View VALN analyst ratings or view top-rated stocks. What is Valneva's stock price target for 2024? 3 Wall Street research analysts have issued twelve-month price targets for Valneva's shares. Their VALN share price targets range from $17.00 to $26.00. On average, they anticipate the company's stock price to reach $21.67 in the next year. This suggests a possible upside of 199.3% from the stock's current price. View analysts price targets for VALN or view top-rated stocks among Wall Street analysts. How have VALN shares performed in 2024? Valneva's stock was trading at $10.37 on January 1st, 2024. Since then, VALN stock has decreased by 30.2% and is now trading at $7.24. View the best growth stocks for 2024 here. When is Valneva's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our VALN earnings forecast. How were Valneva's earnings last quarter? Valneva SE (NASDAQ:VALN) released its earnings results on Wednesday, March, 20th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of $0.20 by $0.70. The firm had revenue of $45.12 million for the quarter, compared to the consensus estimate of $45.06 million. Valneva had a negative net margin of 65.99% and a negative trailing twelve-month return on equity of 59.48%. What guidance has Valneva issued on next quarter's earnings? Valneva updated its FY 2024 earnings guidance on Wednesday, March, 20th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $172.2 million-$193.8 million, compared to the consensus revenue estimate of $245.0 million. When did Valneva IPO? Valneva (VALN) raised $99 million in an initial public offering on Thursday, May 6th 2021. The company issued 3,500,000 shares at $28.24 per share. Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. acted as the underwriters for the IPO. Who are Valneva's major shareholders? Valneva's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include General American Investors Co. Inc. (0.51%). How do I buy shares of Valneva? Shares of VALN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VALN) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valneva SE Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.